A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma)

By afschroeder • July 9, 2026

Shin SJ, Lee JL, Powles T, Martin-Liberal J, Morales-Barrera R, Drakaki A, Friedlander T, Joly F, Shah SA, Vuky J, Ianculescu I, Michielin F, Gan X, Bamias A. A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma). ESMO Open. 2026 Jul 8;11(8):108303. doi: 10.1016/j.esmoop.2026.108303. Epub ahead of print. PMID: 42418909.

Tags: Atezolizumab, Hematology/Oncology, locally advanced or metastatic, MORPHEUS, prior platinum, Publications, Sacituzumab govitecan, urothelial carcinoma

Psychosocial burden in cancer survivors

Ganz PA. Psychosocial burden in cancer survivors. Nat Rev Cancer. 2026 Oct 1. doi: 10.1038/s41568-026-00986-0. Epub ahead of print. PMID: 42823480.

Delta-9-tetrahydrocannabinol alleviates inflammation by modulating immune responses in LPS-induced murine inflammation model

Tomer S, Harding J, Wang L, Kedia N, Cook E, Le V, Platt C, Le J, Tien N, Patalay K, Langfelder P, Yang XW, Zhang[...]

Self-Reported Cancer-Related Cognitive Impairment and Psychosocial Symptom Burden in Survivors of Head and Neck Cancer

Lin ME, Stenzel J, Delavary D, St John MA, Wong DJ, Ganz PA, Brauer ER. Self-Reported Cancer-Related Cognitive Impairment and Psychosocial Symptom Burden in Survivors[...]